11月3日 - ** 药物开发商 Terns Pharmaceuticals TERN.O 的股票在早盘交易中上涨 82%，达到 15.07 美元
** 公司称慢性髓性白血病实验药物TERN-701的早期试验结果令人鼓舞
** TERN 称 64% 的慢性髓性白血病患者在 24 周前获得了主要分子反应(MMR)
** MMR意味着患者血液中的白血病水平已降至很低，表明治疗有效地控制了病情
** 即使是之前接受过 asciminib 和 ponatinib 等疗法失败的患者，MMR 率也很高。
** 慢性髓性白血病是一种骨髓制造过多异常白细胞的血癌。
** 包括本交易日的走势在内，该股今年累计上涨约 171
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.